40,047 Shares in Aerovate Therapeutics, Inc. $AVTE Acquired by Nuveen LLC

Nuveen LLC acquired a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 40,047 shares of the company's stock, valued at approximately $101,000. Nuveen LLC owned approximately 0.14% of Aerovate Therapeutics at the end of the most recent reporting period.Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Two Sigma Advisers LP grew its holdings in Aerovate Therapeutics by 38.5% in the 4th quarter. Two Sigma Advisers LP now owns 153,600 shares of the company's stock worth $407,000 after buying an additional 42,700 shares in the last quarter. Northern Trust Corp grew its holdings in Aerovate Therapeutics by 6.3% in the 4th quarter. Northern Trust Corp now owns 106,692 shares of the company's stock worth $283,000 after buying an additional 6,296 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Aerovate Therapeutics in the 4th quarter worth approximately $145,000. Rhumbline Advisers lifted its position in Aerovate Therapeutics by 67.3% in the first quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock worth $57,000 after purchasing an additional 9,154 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Aerovate Therapeutics in the fourth quarter worth approximately $52,000. Get Aerovate Therapeutics alerts:Aerovate Therapeutics Price PerformanceAVTE opened at $7.77 on Monday. The company has a market capitalization of $225.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.95. Aerovate Therapeutics, Inc. has a 1-year low of $56.35 and a 1-year high of $105.00. The business has a 50 day moving average price of $8.43 and a two-hundred day moving average price of $35.97. Aerovate Therapeutics Profile (Free Report)Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.Read MoreFive stocks we like better than Aerovate TherapeuticsMarket Cap Calculator: How to Calculate Market CapUnion Pacific: Laying the Tracks for America's Industrial RenewalWhat Percentage Gainers Tell Investors and Why They Don’t Tell the Whole StoryTransDigm’s Edge: From Spare Parts to Sky-High ProfitsREIT Stocks - Best REIT Stocks to Add to Your Portfolio TodaySpire Global: Tiny Satellites, Big Buy Ratings and UpsideThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Aerovate Therapeutics Right Now?Before you consider Aerovate Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here